ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
化学式:
C6H5C(C2H5)=C(C6H5)C6H4OCH2CH2N(CH3)2
CAS番号:
分子量:
371.51
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
234-118-0
MDL number:
製品名
タモキシフェン, analytical standard
InChI key
NKANXQFJJICGDU-QPLCGJKRSA-N
InChI
1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
SMILES string
CC\C(c1ccccc1)=C(/c2ccccc2)c3ccc(OCCN(C)C)cc3
grade
analytical standard
assay
≥98.0% (HPLC)
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
impurities
≤0.5% water
mp
97-98 °C (lit.)
application(s)
forensics and toxicology
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Quality Level
Gene Information
human ... ESR1(2099)
類似した製品をお探しですか? 訪問 製品比較ガイド
Biochem/physiol Actions
プロテインキナ-ゼCインヒビタ-。ヒト悪性グリオ-マ細胞株のアポト-シスを誘導します。タモキシフェンおよびその代謝産物である4-ヒドロキシタモキシフェンは選択的エストロゲン応答修飾因子(SERM)であり、乳腺のエストロゲンアンタゴニストとして作用します。乳癌細胞におけるエストラジオ-ル刺激性のVEGF産生を阻害します。
乳腺のエストロゲンアンタゴニストです。乳癌細胞におけるエストラジオ-ル刺激性のVEGF産生を阻害します。プロテインキナ-ゼCインヒビタ-。
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
signalword
Danger
hcodes
Hazard Classifications
Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Repr. 1B
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Jack Cuzick et al.
The Lancet. Oncology, 16(1), 67-75 (2014-12-17)
Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up. We report the long-term follow-up of the
L Binkhorst et al.
Clinical pharmacology and therapeutics, 92(4), 431-433 (2012-08-23)
Traditionally, all patients treated with tamoxifen receive a standard dose. A number of studies claimed a clinically relevant impact of cytochrome P450 2D6 (CYP2D6) genotype on outcome, and therefore genotyping before tamoxifen therapy was advocated. Recent data showed that adequate
Takeo Nakaya et al.
Cancer research, 74(10), 2882-2891 (2014-03-15)
The intestinal epithelium maintains homeostasis by a self-renewal process involving resident stem cells, including Lgr5(+) crypt-base columnar cells, but core mechanisms and their contributions to intestinal cancer are not fully defined. In this study, we examined a hypothesized role for
Karin Beelen et al.
Breast cancer research : BCR, 16(1), R13-R13 (2014-01-29)
Inhibitors of the phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway can overcome endocrine resistance in estrogen receptor (ER) α-positive breast cancer, but companion diagnostics indicating PI3K/AKT/mTOR activation and consequently endocrine resistance are lacking. PIK3CA mutations frequently occur in ERα-positive
Wataru Ise et al.
Proceedings of the National Academy of Sciences of the United States of America, 111(32), 11792-11797 (2014-07-30)
In primary humoral responses, B-cell lymphoma 6 (Bcl6) is a master regulator of follicular helper T (TFH) cell differentiation; however, its activation mechanisms and role in memory responses remain unclear. Here we demonstrate that survival of CXCR5(+) TFH memory cells
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)
